
EquitySector - HealthcareVery High Risk
Regular
NAV (10-Apr-26)
Returns (Since Inception)
Fund Size
₹442 Cr
Expense Ratio
2.34%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+10.16%
+9.59% (Cat Avg.)
Since Inception
+13.31%
— (Cat Avg.)
| Equity | ₹439.53 Cr | 99.38% |
| Others | ₹2.74 Cr | 0.62% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹61.5 Cr | 13.91% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹33.24 Cr | 7.51% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹30.79 Cr | 6.96% |
| Divi's Laboratories Ltd | Equity | ₹26.76 Cr | 6.05% |
| Acutaas Chemicals Ltd | Equity | ₹22.52 Cr | 5.09% |
| Fortis Healthcare Ltd | Equity | ₹20.67 Cr | 4.67% |
| Lupin Ltd | Equity | ₹18.51 Cr | 4.19% |
| Park Medi World Ltd | Equity | ₹15.41 Cr | 3.48% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹14.84 Cr | 3.35% |
| Cipla Ltd | Equity | ₹14.69 Cr | 3.32% |
| Sai Life Sciences Ltd | Equity | ₹13.61 Cr | 3.08% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹12.43 Cr | 2.81% |
| Aurobindo Pharma Ltd | Equity | ₹12.39 Cr | 2.80% |
| Ajanta Pharma Ltd | Equity | ₹11.78 Cr | 2.66% |
| Jubilant Pharmova Ltd | Equity | ₹11.02 Cr | 2.49% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹10.66 Cr | 2.41% |
| Alkem Laboratories Ltd | Equity | ₹10.6 Cr | 2.40% |
| Anthem Biosciences Ltd | Equity | ₹10.5 Cr | 2.37% |
| Gland Pharma Ltd | Equity | ₹9.33 Cr | 2.11% |
| Corona Remedies Ltd | Equity | ₹8.56 Cr | 1.93% |
| Emcure Pharmaceuticals Ltd | Equity | ₹7.98 Cr | 1.80% |
| Marksans Pharma Ltd | Equity | ₹7.84 Cr | 1.77% |
| Rubicon Research Ltd | Equity | ₹7.73 Cr | 1.75% |
| Mankind Pharma Ltd | Equity | ₹7.62 Cr | 1.72% |
| Dr Reddy's Laboratories Ltd | Equity | ₹6.27 Cr | 1.42% |
| Zydus Lifesciences Ltd | Equity | ₹6.1 Cr | 1.38% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹5.55 Cr | 1.26% |
| Triparty Repo | Cash - Repurchase Agreement | ₹5.5 Cr | 1.24% |
| Innova Captab Ltd | Equity | ₹5.31 Cr | 1.20% |
| Rainbow Childrens Medicare Ltd | Equity | ₹5 Cr | 1.13% |
| Orchid Pharma Ltd | Equity | ₹4.82 Cr | 1.09% |
| Laxmi Dental Ltd | Equity | ₹4.51 Cr | 1.02% |
| Net Current Assets/(Liabilities) | Cash | ₹-2.76 Cr | 0.62% |
| Medi Assist Healthcare Services Ltd | Equity | ₹0.99 Cr | 0.22% |
Large Cap Stocks
35.01%
Mid Cap Stocks
21.94%
Small Cap Stocks
42.42%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹417.02 Cr | 94.29% |
| Basic Materials | ₹22.52 Cr | 5.09% |
Standard Deviation
This fund
--
Cat. avg.
16.46%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.96
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.70
Higher the better

Since December 2023
Since March 2024
ISIN INF174KA1PW4 | Expense Ratio 2.34% | Exit Load No Charges | Fund Size ₹442 Cr | Age 2 years 4 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹6,16,950 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments